Ostatní
Návod 
Agenus Inc.
AGEN
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
0.1B
Obrat
0B
Zisk
0B
Aktiva
0B
Dluh
0B
ROE
13%
ROA
-15%
PE
1139
PS
1
Cena 1R
1-7
⌀ Cena
4.15
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
10-03-2026
Poslední dividenda
Profil
Agenus Inc., společnost zabývající se klinickým stadiem imunoonkologie, objevuje a vyvíjí imunoonkologické přípravky ve Spojených státech i v mezinárodním měřítku. Společnost nabízí Retrocyte Display, platformu pro expresi protilátek pro identifikaci plně lidských a humanizovaných monoklonálních protilátek; a displejové technologie. Vyvíjí očkovací programy zahrnující kandidáta na vakcínu Prophage a adjuvans QS- 21 Stimulon, adjuvans na vakcínu na bázi saponinu. Společnost také vyvíjí Balstilimab, antagonistu anti-PD- 1, který dokončil klinickou studii fáze II k léčbě cervikálního karcinomu druhé linie; AGEN1181, monospecifickou protilátku proti CTLA- 4, která je v klinické studii fáze 1/2; AGEN2373, monospecifickou protilátku proti CD137, která je v klinické studii fáze 1; AGEN1423, nádorové mikroprostředí podmíněné anti-CD73/TGFß TRAP bifunkční protilátku, která dokončila klinickou studii fáze 1; AGEN1777, biizopecifické protilátky proti TIGIT a AGEN1327, lidskou monoklonální protilátku protilátka. Kromě toho společnost vyvíjí INCAGN1876, monospecifickou protilátku proti GITR; INCAGN1949, monospecifickou protilátku proti OX40; INCAGN2390, monospecifickou protilátku proti TIM-3; INCAGN2385, monospecifickou protilátku proti LAG-3; MK-4830, monospecifickou protilátku zaměřenou na ILT4; Agent 797, iNKT buňky, které jsou ve fázi 1 klinické studie na solidní tumory, mnohočetný myelom a virový ARDS, stejně jako v klinickém stadiu k léčbě hematologických malignit a mnohočetných myelomů/B buněk a AGEN1884, monospecifická protilátka proti CTLA- 4 první generace. Společnost Agenus Inc. působí pod značkami ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display a Stimulon. Spolupracuje s firmami Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA a Gilead Sciences, Inc. Společnost byla dříve známá jako Antigenics Inc. a v lednu 2011 změnila název na Agenus Inc. Společnost byla založena v roce 1994 a sídlí v Lexingtonu v Massachusetts.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
316
Založení
2000-02-08
Podobné společnosti
$ 2.12
+ $ 0.01
$ 1.88
- $ 0.02
$ 2.06
- $ 0.03
$ 1.31
+ $ 0.03
$ 1.64
+ $ 0.04
$ 1.07
- $ 0.00
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 114.2 | 114.2 | 103.5 | 156.3 | 98.0 | 295.7 | 88.2 | 150.0 | 36.8 | 42.9 | 22.6 | 24.8 | 7.0 | 3.0 | 16.0 | 2.8 | 3.4 | |
| Cost of Revenues | 73.4 | 11.0 | 156.0 | 237.7 | 197.3 | 182.1 | 145.0 | 168.3 | 124.6 | 116.1 | 95.0 | 70.4 | 22.3 | 13.5 | 11.2 | 0.0 | 0.1 | |
| Gross Profit | 40.7 | 103.2 | -52.6 | -81.4 | -99.2 | 113.6 | -56.8 | -18.3 | -87.8 | -73.2 | -72.4 | -45.6 | -15.4 | -10.5 | 4.7 | 2.8 | 3.2 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 34.2 | 30.2 | 25.7 | 24.1 | 26.8 | 25.1 | 23.5 | 28.0 | 83.8 | 24.3 | |
| Cost of Revenues | 0.6 | 24.2 | 27.0 | 21.7 | 33.9 | 41.2 | 36.9 | 3.5 | 5.5 | 51.7 | |
| Gross Profit | 33.6 | 6.0 | -1.3 | 2.4 | -7.1 | -16.1 | -13.4 | 24.5 | 78.3 | -27.4 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 234.6 | 17.0 | 0.0 | 142.6 | 168.3 | 124.6 | 116.1 | 95.0 | 70.4 | 22.3 | 13.0 | 10.6 | 11.0 | 12.9 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 78.7 | 81.0 | 76.4 | 59.2 | 46.0 | 37.3 | 33.7 | 33.1 | 28.4 | 21.3 | 14.5 | 11.5 | 10.8 | 12.1 | |
| Depreciation & Amortization | 10.0 | 10.0 | 13.3 | 13.6 | 18.7 | 6.8 | 6.5 | 12.5 | 6.3 | 6.0 | 4.9 | 14.2 | 1.6 | 0.6 | 1.6 | 2.3 | 3.4 | |
| Total Operating Expenses | 60.9 | 123.7 | 67.9 | 78.2 | 81.0 | 76.4 | 59.2 | 46.0 | 37.3 | 33.7 | 33.1 | 28.4 | 21.3 | 14.5 | 11.5 | 21.8 | 25.0 | |
| Operating Income | -20.2 | -20.6 | -120.5 | -159.5 | -179.4 | 42.3 | -117.2 | -70.1 | -123.8 | -103.8 | -107.5 | -80.7 | -43.3 | -25.0 | -6.7 | -19.1 | -21.8 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 66.7 | 3.4 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 16.0 | 18.9 | ||
| Depreciation & Amortization | 0.6 | 3.0 | 3.2 | 3.2 | 3.3 | 3.3 | 3.4 | 3.4 | 5.2 | 2.9 | ||
| Total Operating Expenses | 19.2 | 10.5 | 15.4 | 15.7 | 18.8 | 15.4 | 16.8 | 57.4 | 82.7 | 18.9 | ||
| Operating Income | 14.4 | -4.5 | -16.7 | -13.3 | -25.9 | -31.5 | -30.2 | -32.9 | -4.4 | -46.3 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 0.0 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Interest Expense | 55.3 | 55.6 | 117.6 | 97.9 | 61.9 | 65.7 | 61.1 | 41.5 | 25.3 | 18.9 | 17.3 | 6.6 | 1.3 | 2.4 | 4.7 | 4.2 | 4.9 | |
| Other Expense | 17.1 | 17.5 | -111.8 | -97.9 | -51.2 | -71.0 | -65.7 | -41.4 | -11.6 | -13.7 | -21.5 | -13.9 | -5.9 | -5.1 | -4.6 | 0.0 | 4.7 | |
| IBT | -3.1 | -3.1 | -232.3 | -257.4 | -230.7 | -28.7 | -182.9 | -111.6 | -162.0 | -120.7 | -127.0 | -87.9 | -42.5 | -30.1 | -11.3 | -24.1 | -22.7 | |
| Income Tax Expense | 0.0 | 0.0 | 0.0 | 0.0 | 40.9 | 66.0 | 57.2 | 37.6 | -12.9 | -9.2 | -3.0 | -5.4 | 5.1 | -0.6 | -1.6 | 4.2 | 0.2 | |
| Net Income | 0.1 | 0.1 | -227.2 | -245.8 | -271.5 | -94.7 | -240.1 | -149.1 | -159.7 | -120.7 | -127.0 | -87.9 | -42.5 | -30.1 | -11.3 | -23.3 | -21.9 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 18.6 | ||
| Interest Expense | 16.0 | 13.2 | 13.3 | 12.8 | 20.7 | 35.7 | 31.7 | 29.5 | 44.6 | 18.6 | ||
| Other Expense | -25.0 | 68.5 | -13.3 | -13.1 | -20.9 | -35.7 | -24.6 | -30.6 | -44.4 | -18.2 | ||
| IBT | -10.6 | 63.9 | -30.0 | -26.4 | -46.8 | -67.2 | -54.8 | -63.5 | -48.6 | -64.5 | ||
| Income Tax Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.3 | 16.7 | ||
| Net Income | -10.6 | 63.9 | -28.0 | -25.3 | -45.9 | -66.4 | -53.1 | -61.9 | -46.3 | -62.2 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $-13.75 | $-19.27 | $-8.27 | $-27.84 | $-22.10 | $-28.83 | $-24.53 | $-29.17 | $-22.47 | $-14.22 | $-20.21 | $-0.48 | $-1.17 | $-1.36 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $-13.75 | $-19.27 | $-8.27 | $-27.84 | $-22.10 | $-28.83 | $-24.53 | $-29.17 | $-22.47 | $-14.22 | $-20.21 | $-0.48 | $-1.17 | $-1.36 | |
| Shares Outstanding | 35.3 | 29.7 | 21.5 | 17.9 | 14.1 | 11.4 | 8.6 | 6.7 | 5.5 | 4.9 | 4.4 | 3.9 | 3.0 | 1.5 | 23.6 | 19.9 | 16.1 | |
| Diluted Shares Outstanding | 35.3 | 29.7 | 21.5 | 17.9 | 14.1 | 11.4 | 8.6 | 6.7 | 5.5 | 4.9 | 4.4 | 3.9 | 3.0 | 1.5 | 23.6 | 19.9 | 16.1 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-2.48 | $-3.29 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-2.48 | $-3.29 | ||
| Shares Outstanding | 35.3 | 31.9 | 28.1 | 24.5 | 22.5 | 21.6 | 21.1 | 19.9 | 18.7 | 18.9 | ||
| Diluted Shares Outstanding | 35.3 | 32.9 | 28.1 | 24.5 | 22.5 | 21.6 | 21.1 | 19.9 | 18.7 | 18.9 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 93.7 | 40.4 | 76.1 | 178.7 | 291.9 | 99.9 | 61.8 | 53.1 | 60.2 | 76.4 | 171.7 | 40.2 | 27.4 | 21.5 | 10.7 | 19.8 | |
| Short Term Investments | 0.0 | 0.0 | 0.4 | 14.7 | 15.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.0 | 35.0 | 14.5 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Cash & ST Investments | 93.7 | 40.4 | 76.1 | 193.4 | 306.9 | 99.9 | 61.8 | 53.1 | 60.2 | 76.4 | 171.7 | 40.2 | 27.4 | 21.5 | 10.7 | 19.8 | |
| Accounts Receivable | 0.7 | 0.4 | 25.8 | 2.7 | 1.5 | 1.2 | 16.3 | 0.9 | 1.1 | 11.4 | 9.8 | 1.2 | 0.0 | 0.6 | 0.5 | 0.0 | |
| Inventory | 0.0 | 0.0 | 0.0 | 13.8 | 20.4 | 10.7 | 7.4 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.7 | 0.0 | 0.0 | 0.0 | |
| Other Current Assets | 5.6 | 4.7 | 10.5 | 3.2 | 3.2 | 2.0 | 1.0 | 1.5 | 1.1 | 0.8 | 0.6 | 1.1 | 0.2 | 0.0 | 0.7 | 0.3 | |
| Total Current Assets | 100.0 | 45.6 | 112.4 | 213.1 | 332.0 | 113.8 | 86.5 | 74.8 | 73.6 | 91.3 | 184.1 | 42.7 | 28.2 | 22.6 | 12.0 | 20.9 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 3.5 | 9.5 | 18.5 | 40.4 | 44.8 | 93.7 | 52.9 | 76.1 | 106.3 | 143.2 | |
| Short Term Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 14.6 | |
| Total Cash & ST Investments | 3.5 | 9.5 | 18.5 | 40.4 | 44.8 | 93.7 | 52.9 | 76.1 | 106.3 | 157.9 | |
| Accounts Receivable | 6.3 | 0.7 | 0.4 | 0.4 | 0.2 | 0.7 | 0.5 | 25.8 | 1.0 | 1.3 | |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 15.9 | 8.7 | |
| Other Current Assets | 124.2 | 3.1 | 4.3 | 4.7 | 5.2 | 5.6 | 7.0 | 10.5 | 18.2 | 11.5 | |
| Total Current Assets | 134.0 | 13.3 | 23.1 | 45.6 | 50.2 | 100.0 | 60.4 | 112.4 | 125.6 | 170.7 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 156.5 | 147.4 | 163.0 | 164.3 | 91.1 | 60.3 | 33.7 | 25.1 | 26.2 | 25.6 | 15.3 | 6.0 | 5.6 | 5.2 | 4.1 | 6.2 | |
| Goodwill | 24.7 | 24.1 | 24.7 | 25.5 | 24.9 | 25.5 | 23.2 | 22.9 | 23.0 | 22.4 | 22.8 | 17.9 | 2.6 | 2.6 | 2.6 | 2.6 | |
| Intangible Assets | 4.1 | 3.4 | 4.4 | 6.2 | 8.5 | 10.9 | 10.5 | 12.3 | 31.8 | 16.4 | 18.8 | 6.8 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 3.6 | 0.0 | 3.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Long-Term Assets | 3.4 | 5.8 | 6.1 | 4.5 | 9.5 | 4.1 | 1.4 | 1.2 | 1.2 | 1.3 | 1.3 | 1.2 | 1.3 | 1.3 | 1.1 | 1.3 | |
| Total Long-Term Assets | 192.4 | 180.7 | 201.5 | 200.4 | 134.0 | 100.7 | 68.8 | 61.6 | 82.2 | 65.7 | 58.1 | 31.9 | 9.4 | 9.1 | 7.8 | 10.1 | |
| Total Assets | 292.4 | 226.3 | 313.9 | 413.6 | 466.0 | 214.5 | 155.3 | 136.4 | 138.4 | 157.0 | 242.2 | 74.5 | 34.8 | 34.7 | 19.8 | 30.9 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 24.0 | 139.1 | 144.1 | 147.4 | 153.1 | 156.5 | 159.7 | 163.0 | 169.7 | 173.9 | |
| Goodwill | 24.1 | 24.1 | 24.1 | 24.1 | 24.7 | 24.7 | 24.7 | 24.7 | 24.7 | 24.7 | |
| Intangible Assets | 3.1 | 3.2 | 3.3 | 3.4 | 4.0 | 4.1 | 4.2 | 4.4 | 4.5 | 5.0 | |
| Long-Term Investments | 30.5 | 0.9 | 4.5 | 0.0 | 3.6 | 1.5 | 3.7 | 3.7 | 3.7 | 2.7 | |
| Other Long-Term Assets | 18.2 | 4.5 | 1.1 | 5.8 | 3.0 | 5.5 | 3.9 | 5.7 | 11.1 | 9.3 | |
| Total Long-Term Assets | 99.9 | 171.9 | 177.1 | 180.7 | 188.3 | 192.4 | 196.2 | 201.5 | 209.9 | 212.9 | |
| Total Assets | 233.9 | 185.2 | 200.2 | 226.3 | 238.5 | 292.4 | 256.6 | 313.9 | 335.5 | 383.6 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 50.8 | 61.5 | 61.4 | 40.9 | 30.5 | 17.0 | 13.6 | 13.6 | 8.1 | 5.4 | 4.5 | 1.7 | 0.8 | 0.6 | 0.8 | 0.7 | |
| Short-Term Debt | 171.6 | 9.8 | 2.7 | 2.5 | 3.4 | 2.8 | 2.0 | 0.1 | 20.6 | 0.1 | 0.1 | 1.3 | 3.5 | 0.2 | 0.2 | 0.1 | |
| Other Current Liabilities | 48.2 | 150.1 | 191.7 | 133.2 | 110.7 | 92.9 | 77.5 | 52.5 | 23.2 | 32.7 | 20.5 | 6.1 | 4.3 | 2.4 | 2.2 | 3.0 | |
| Current Liabilities | 270.7 | 221.4 | 255.9 | 189.0 | 156.9 | 129.9 | 122.2 | 68.1 | 56.4 | 40.9 | 28.9 | 9.2 | 10.3 | 4.8 | 4.8 | 5.4 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 85.3 | 74.4 | 64.2 | 61.5 | 45.9 | 50.8 | 50.7 | 61.4 | 40.9 | 52.5 | |
| Short-Term Debt | 11.8 | 14.0 | 5.2 | 9.8 | 182.9 | 25.1 | 160.7 | 2.7 | 13.1 | 12.4 | |
| Other Current Liabilities | 190.0 | 146.2 | 138.8 | 150.1 | 41.9 | 194.7 | 44.6 | 191.7 | 139.4 | 131.3 | |
| Current Liabilities | 287.1 | 234.6 | 208.3 | 221.4 | 270.6 | 270.7 | 256.0 | 255.9 | 198.4 | 204.1 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 184.2 | 85.0 | 80.0 | 75.9 | 54.9 | 52.9 | 21.4 | 13.2 | 142.4 | 130.5 | 114.3 | 4.8 | 5.3 | 35.7 | 32.7 | 34.1 | |
| Capital Leases | 55.8 | 61.7 | 65.1 | 65.3 | 44.7 | 36.0 | 9.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Def. Tax Liability | 55.8 | 0.0 | 0.0 | 0.0 | 0.0 | 26.9 | 26.9 | 182.8 | 0.0 | 0.0 | 0.0 | 15.3 | 18.8 | 0.0 | 0.0 | 0.8 | |
| Total Liabilities | 513.3 | 532.7 | 462.3 | 468.5 | 418.0 | 426.0 | 386.7 | 310.9 | 214.2 | 196.1 | 171.5 | 51.5 | 39.3 | 46.7 | 40.6 | 45.6 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 34.0 | 77.3 | 86.8 | 85.0 | 237.7 | 55.8 | 187.0 | 204.6 | 75.9 | 74.9 | |
| Capital Leases | 11.6 | 57.4 | 58.5 | 61.7 | 0.0 | 55.8 | 61.8 | 67.2 | 75.9 | 74.1 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 67.2 | 0.0 | 0.0 | |
| Total Liabilities | 514.8 | 521.5 | 522.6 | 532.7 | 510.3 | 513.3 | 446.9 | 462.3 | 450.8 | 460.4 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.2 | 0.2 | 3.9 | 3.1 | 2.6 | 2.0 | 1.4 | 1.2 | 1.0 | 0.9 | 0.9 | 0.6 | 0.4 | 0.2 | 0.2 | 1.1 | |
| Retained Earnings | -2,070.6 | -2,182.9 | -1,955.7 | -1,709.9 | -1,489.8 | -1,465.9 | -1,285.0 | -1,177.3 | -1,026.5 | -905.3 | -779.2 | -691.3 | -649.1 | -619.0 | -607.7 | -584.4 | |
| Comprehensive Income | -1.0 | -1.4 | -1.0 | 0.9 | 1.5 | 2.8 | -1.3 | -1.5 | -2.2 | -1.5 | -2.1 | -2.0 | -27.6 | -27.4 | -26.1 | -25.0 | |
| Total Common Equity | -241.3 | -326.4 | -160.3 | -61.3 | 34.4 | -203.7 | -225.4 | -172.5 | -75.8 | -39.1 | 70.7 | 23.0 | -4.5 | -17.6 | -26.4 | -14.7 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 3.9 | 3.8 | 3.7 | |
| Retained Earnings | -2,172.2 | -2,236.1 | -2,208.1 | -2,182.9 | -2,137.0 | -2,070.6 | -2,017.6 | -1,955.7 | -1,909.4 | -1,847.2 | |
| Comprehensive Income | -1.6 | -1.5 | -1.5 | -1.4 | -1.3 | -1.0 | -1.1 | -1.0 | -1.0 | -0.7 | |
| Total Common Equity | -274.1 | -354.6 | -341.8 | -326.4 | -292.3 | -241.3 | -201.4 | -160.3 | -129.1 | -93.2 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 411.6 | 94.9 | 78.0 | 78.4 | 58.3 | 55.7 | 23.4 | 13.4 | 163.0 | 130.7 | 114.5 | 6.0 | 8.9 | 35.9 | 32.9 | 34.2 | |
| Book Value | -220.8 | -306.4 | -148.4 | -54.9 | 47.9 | -211.5 | -231.3 | -174.5 | -75.8 | -39.1 | 70.7 | 23.0 | -4.5 | -12.0 | -20.8 | -14.7 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | -6.7 | 18.3 | 19.5 | 20.0 | 20.5 | 20.5 | 11.1 | 11.9 | 13.8 | 16.4 | |
| Book Value | -274.1 | -354.6 | -341.8 | -326.4 | -292.3 | -241.3 | -201.4 | -160.3 | -129.1 | -93.2 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -225.8 | -232.3 | -232.3 | -245.8 | -230.7 | -28.7 | -182.9 | -111.6 | -162.0 | -120.7 | -127.0 | -87.9 | -42.5 | -30.1 | -11.3 | -23.3 | -21.9 | |
| Depreciation & Amortization | 14.8 | 13.3 | 13.3 | 13.6 | 6.9 | 6.8 | 7.2 | 6.7 | 6.3 | 6.0 | 4.9 | 14.2 | 1.6 | 0.6 | 1.6 | 2.3 | 3.4 | |
| Stock-Based Compensation | 19.5 | 17.4 | 17.4 | 22.9 | 18.3 | 19.6 | 10.4 | 9.9 | 7.6 | 12.4 | 13.2 | 7.4 | 4.7 | 4.1 | 4.3 | 2.6 | 3.2 | |
| Change Working Capital | 18.2 | 27.3 | 32.6 | 10.8 | 24.1 | -9.7 | 9.0 | 58.7 | 0.2 | -6.5 | 10.4 | 6.6 | -6.0 | 1.3 | 3.3 | -2.1 | 0.4 | |
| Change In Accounts Receivable | 0.6 | -1.7 | 25.3 | -23.5 | 0.1 | -0.4 | 16.2 | -15.4 | 0.2 | 10.2 | -1.5 | -9.3 | 0.0 | 0.6 | -0.6 | 0.0 | 0.0 | |
| Change In Accounts Payable | 4.7 | 23.5 | 2.0 | 21.4 | 6.5 | 10.8 | 2.8 | -0.2 | 5.4 | 1.6 | 0.4 | 2.7 | 0.0 | 0.2 | -0.2 | 0.0 | -0.2 | |
| Change In Inventories | -5.4 | 0.0 | 0.0 | 0.0 | 0.0 | -6.2 | 3.6 | 0.1 | 0.0 | 0.0 | 17.6 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | 0.3 | |
| Other Non-cash Items | 16.7 | 15.9 | 10.6 | -25.7 | 5.9 | 31.7 | 14.3 | 17.6 | 6.0 | 14.5 | 18.5 | 17.8 | 4.0 | 1.8 | 3.1 | -19.1 | 2.1 | |
| Cash from Operations | -182.0 | 0.0 | 0.0 | -224.2 | -175.4 | 10.1 | -139.1 | -18.7 | -131.1 | -94.2 | -80.0 | -47.2 | -38.2 | -19.5 | 1.0 | -16.2 | -14.8 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -239.8 | 63.9 | -30.0 | -26.4 | -45.9 | -67.2 | -54.8 | -63.5 | -46.3 | -64.5 | |
| Depreciation & Amortization | 3.9 | 3.0 | 3.2 | 3.2 | 3.3 | 3.3 | 3.4 | 3.4 | 5.2 | 2.9 | |
| Stock-Based Compensation | 7.1 | 3.2 | 3.6 | 3.5 | 0.0 | 4.5 | 4.0 | 4.2 | 5.5 | 5.9 | |
| Change Working Capital | -3.8 | 12.5 | 13.7 | 4.9 | 14.1 | -2.0 | 5.7 | 14.8 | 6.2 | -8.5 | |
| Change In Accounts Receivable | -1.7 | 0.2 | -0.3 | 0.1 | -0.3 | 0.5 | -0.2 | 25.3 | -24.8 | 0.3 | |
| Change In Accounts Payable | -3.3 | 14.1 | 10.1 | 2.6 | 15.7 | -5.0 | 2.0 | -10.7 | 20.5 | -7.1 | |
| Change In Inventories | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.6 | -2.8 | |
| Other Non-cash Items | 216.0 | -97.4 | -10.7 | -10.9 | -0.2 | 8.0 | 3.5 | 3.0 | 9.2 | -1.0 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -40.4 | -65.2 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | 1.2 | -0.6 | -0.6 | -10.0 | -53.1 | -33.8 | -3.5 | -4.7 | -3.6 | -3.1 | -12.5 | -3.6 | -2.8 | -0.8 | -0.1 | -0.1 | -0.1 | |
| Acquisitions | 3.0 | 0.0 | 0.0 | 0.0 | -2.9 | 0.0 | -1.0 | 0.0 | 0.0 | 0.0 | 0.0 | -7.2 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Investments | -5.4 | 0.0 | 0.0 | -20.0 | -24.6 | -15.0 | 0.0 | 0.0 | 0.0 | -14.9 | -54.9 | -35.0 | -14.5 | 0.0 | 0.0 | -5.0 | -30.0 | |
| Sales of Investment | 15.5 | 0.6 | 0.6 | 30.0 | 25.0 | 0.0 | 0.0 | 0.0 | 0.0 | 20.0 | 85.0 | 14.5 | 0.0 | 0.5 | 0.0 | 5.0 | 40.0 | |
| Other Investing Activities | 18.5 | 0.0 | 0.0 | 3.4 | 22.0 | 5.7 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | |
| Cash from Investing | 14.4 | 0.0 | 0.0 | 3.4 | -33.6 | -43.2 | -4.4 | -4.7 | -3.6 | 2.1 | 17.6 | -31.2 | -16.8 | -0.4 | -0.1 | 0.0 | 9.9 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -0.6 | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 | -0.5 | 0.0 | 5.2 | -3.5 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.0 | 0.0 | |
| Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -5.4 | 0.0 | |
| Sales of Investment | 0.5 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.2 | 0.3 | 0.0 | 15.0 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.0 | 15.0 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.8 | 11.5 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | -10.1 | 0.0 | 0.0 | -8.9 | -0.5 | -1.3 | -3.2 | -0.3 | -162.1 | -0.3 | -0.1 | -1.1 | -3.3 | -10.6 | -0.1 | 0.0 | -6.2 | |
| Debt Issued | 334.4 | 94.9 | 16.9 | 8.5 | 20.6 | 3.9 | 35.6 | 10.4 | 12.5 | 32.7 | 16.4 | 109.6 | 0.5 | -16.5 | 3.1 | -1.2 | 40.4 | |
| Issuance of Common Stock | 50.1 | 0.0 | 0.0 | 133.2 | 99.2 | 220.6 | 176.4 | 30.0 | 44.9 | 65.6 | 2.2 | 109.7 | 56.8 | 26.5 | 10.5 | 8.0 | 11.6 | |
| Repurchase of Common Stock | 0.2 | -0.1 | 0.0 | -4.6 | -3.8 | -1.7 | 0.0 | 0.0 | 0.0 | -0.5 | -0.7 | 0.0 | -0.5 | 0.0 | -0.6 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -9.1 | 0.0 | 0.0 | 0.0 | -16.0 | -1.2 | 0.0 | -0.5 | 0.0 | -0.6 | -0.8 | -0.8 | |
| Other Financing Activities | 127.4 | 0.0 | 0.0 | 0.2 | 0.9 | 16.7 | 10.7 | 1.6 | 245.5 | 31.8 | -2.6 | 81.0 | 0.3 | 9.9 | 0.6 | 0.1 | 0.0 | |
| Cash from Financing | 119.3 | 0.0 | 0.0 | 119.9 | 95.8 | 225.3 | 183.9 | 31.3 | 128.3 | 80.5 | -2.5 | 189.6 | 52.8 | 25.8 | 9.8 | 7.2 | 4.5 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.6 | -2.4 | |
| Debt Issued | 45.8 | -45.5 | -0.8 | -2.8 | -325.7 | 339.7 | -266.8 | -2.5 | 263.8 | 4.1 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.0 | 20.4 | |
| Repurchase of Common Stock | -0.1 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7.3 | 18.0 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -48.5 | -35.7 | -35.7 | -101.6 | -113.3 | 192.1 | 40.7 | 8.8 | -7.1 | -11.3 | -65.3 | 111.0 | -1.6 | 5.9 | 10.7 | -9.0 | -0.3 | |
| Closing Cash Balance | 93.7 | 44.1 | 44.1 | 79.8 | 181.3 | 294.6 | 102.5 | 61.8 | 53.1 | 60.2 | 71.4 | 136.7 | 25.7 | 27.4 | 21.5 | 10.7 | 19.8 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -0.5 | -8.0 | -9.0 | -21.9 | -4.3 | -48.9 | 40.8 | -23.3 | -30.2 | -35.9 | |
| Closing Cash Balance | 3.0 | 5.2 | 13.2 | 22.1 | 40.4 | 48.4 | 97.4 | 56.5 | 76.1 | 110.0 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -180.8 | -158.9 | -158.9 | -234.2 | -228.4 | -23.7 | -142.6 | -23.3 | -134.7 | -97.3 | -92.5 | -50.8 | -41.1 | -20.3 | 0.9 | -16.3 | -14.9 | |
| Real Free Cash Flow | -200.3 | -176.3 | -176.3 | -257.0 | -246.8 | -43.2 | -153.0 | -33.2 | -142.3 | -109.8 | -105.7 | -58.2 | -45.7 | -24.5 | -3.4 | -19.0 | -18.0 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -98.3 | -14.7 | -20.2 | -25.6 | -28.7 | -53.3 | -38.6 | -38.2 | -35.2 | -68.7 | |
| Real Free Cash Flow | -105.4 | -18.0 | -23.8 | -29.1 | -28.7 | -57.8 | -42.7 | -42.4 | -40.7 | -74.6 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | 1139.5 | -31.1 | -1.4 |
| P/S | 1.1 | 124.6 | 9.4 |
| P/B | -0.5 | -25.3 | 5.2 |
| P/FCF | -0.7 | -59.7 | -1.5 |
| Market cap | $0.1 | $0.3 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 19.6 % | 56.4 % | 0 % |
| Debt to Income | 39800.9 % | -167.5 % | 0 % |
| Debt to Free cash flow | -26 % | -231.7 % | 0 % |
| Interest expense percentage | -274.2 % | -21.9 % | 44.7 % |
| Current ratio | 0.5 | 2.4 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | -0 % | 111.4 % | 0 % |
| ROA | 0 % | -65.4 % | 0 % |
| CapEx to Revenue | 0.1 % | 14.1 % | 0 % |
| RaD to Revenue | 0 % | 227.2 % | 0 % |
| ROEM | 361,379.7 | 178091.3 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 0.1 % | -52540.8 % | 68.7 % |
| Operating margin | -56.6 % | -318.9 % | 35.5 % |
| Net margin | -32.9 % | -373.1 % | 9.5 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 202.4 % | 0 % |
| Dividend payout percentage | 0 % | -1429.1 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 32.9 mil | 11.6 mil |
| Employee count | 0.3 tis | 0.2 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
